Sorivudine topical

Drug Profile

Sorivudine topical

Alternative Names: ARYS-01; JA-001

Latest Information Update: 27 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator aRigen
  • Class Antivirals; Nucleosides; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Herpes zoster

Most Recent Events

  • 22 May 2009 Sorivudine topical is no longer licensed to Janus Pharmaceuticals (now Topica Pharmaceuticals) in USA
  • 20 Feb 2007 Interim results from a phase II trial in patients with Herpes zoster added to the adverse events and Viral Infections therapeutic trials sections
  • 07 Dec 2006 Final results from a phase II clinical trial (ARYS-0502) for Herpes zoster added to the Viral Infections therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top